ClinicalTrials.gg
CompletedNCT02525549Updated Nov 2, 2021Results posted

Comparative Safety and Bioequivalence of Two Treatments in the Treatment of Acne Vulgaris

A Phase 3 interventional study of Adapalene and Benzoyl Peroxide Gel and Adapalene and Benzoyl Peroxide Gel (Reference) in Acne, sponsored by Padagis LLC. Completed. Open to participants aged 12 Years to 40 Years. Per ClinicalTrials.gov, last updated 2021-11-02.

Sponsored by Padagis LLC · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
903
Allocation
Randomized
Ages
12 Years to 40 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 30 studies testing adapalene in Acne Vulgaris — none open to participants now, 2 under way, none of them phase 3. Adapalene · Acne Vulgaris.

Enrollment
6th of 30
903 · median 215
Started
2011
with 1 other
Phase 3
9 of 30
none open now
Registered
18th of 30
by date

Among the 30 studies testing adapalene in Acne Vulgaris, this one is the 6th largest by enrollment, is one of 2 that started in 2011, is one of 9 in phase 3, and was the 18th registered.

Acne Vulgaris

791 studies on the registry are indexed under Acne Vulgaris; 93 are open to participants now.

Browse Acne Vulgaris studies →

Open to participants now

None of the 30 studies testing adapalene in Acne Vulgaris is open now. The open studies under Acne Vulgaris, anywhere →

About adapalene

Adapalene: first FDA approval 1996 (DIFFERIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 46 Acne Vulgaris studies recruiting now, 16 (35%) set no upper age limit and 29 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.

This study: 12 Years to 40 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 30 studies testing adapalene in Acne Vulgaris as a file.
02

Study summary

The purpose of this study is to compare the safety and bioequivalence of Perrigo's product to an FDA approved product for the treatment acne vulgaris.

03

Conditions studied

  • Acne

Browse trials for

04

Who can participate

Ages eligible
12 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and non-pregnant female subjects, 12 to 40 years of age (inclusive), with a clinical diagnosis of at least moderate facial acne vulgaris
  • Inflammatory lesion (papules and pustules) count of 20 to 50 (inclusive)
  • Non-inflammatory (open and closed comedones) lesion count of 25 to 100 (inclusive)
  • No more than two nodulocystic lesions (i.e., nodules and cysts) on the face including those present on the nose, were enrolled.
  • Subjects must also have had a Baseline IGA score of 3 or 4 on a severity scale of 0 to 4 to be enrolled.

Exclusion criteria

Exclusion Criteria:

  • Subjects who are pregnant, nursing, or planning a pregnancy within the study participation period.
  • Presence of more than 2 facial Nodulocystic lesions (i.e. nodules and cysts)
  • Subjects with active cystic acne or Polycystic Ovarian Syndrome
  • Presence of any other facial skin condition that, in the Investigator's opinion, might interfere with acne vulgaris diagnosis and/or evaluations (e .g., on the face: rosacea, dermatitis, psoriasis, squamous cell carcinoma, eczema, acneform eruptions caused by medications, acne, steroid folliculitis, or bacterial folliculiti s).
  • Excessive facial hair (e.g. beards, sideburns, moustaches, etc.) that would interfere with diagnosis or assessment of acne vulgaris.
  • Acne conglobata, acne fulminan s, or secondary acne (chloracne, drug-induced acne, etc.)
  • Use of antipruritics including antihistamine, within 24 hours prior to all study visits (Visit l/Baseline through Visit 4).
  • Use of medicated make-up throughout the study and significant change in the use of consumer products within 30 days of study entry and throughout the study (other than study supplied cleanser and lotion).
  • Use within 6 months prior to baseline or during the study of oral retinoids (e.g. Accutane"') or therapeutic vitamin A supplements of greater than 10,000 units/day (multivitamins are allowed).
  • Use within 1 month prior to baseline or during the study of therapeutic vitamin D supplement (multivitamins are allowed).
  • Use within 1 month prior to baseline or during the study of 1) systemic sterOids', 2) systemic antibiotics, 3) systemic treatment for acne vulgaris (other than oral retinoids which require a 6-month washout), or 4) systemic anti-inflammatory agents". (' Intranasal and inhaled corticosteroids do not require a and may be used throughout the study if at a stable and standard dose. "Subjects may use Acetaminophen for pain relief, as needed, throughout the study)
  • Use within 14 days prior to baseline or during the study of 1) topical sterOids, 2) topical retinoids, 3) topical acne treatments including over-the-counter preparation (e.g. azelaic acid,etc.) 4)a-hydroxy/glycolic acid, 5) benzoyl peroxide, 6) topical anti-inflammatory agents, or 7) topical antibiotics.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
903 participants (actual)

Study arms

  • Experimental
    Test product

    Adapalene and Benzoyl Peroxide Gel

    Drug: Adapalene and Benzoyl Peroxide Gel

  • Active comparator
    Reference product

    Adapalene and Benzoyl Peroxide Gel (Reference)

    Drug: Adapalene and Benzoyl Peroxide Gel (Reference)

  • Placebo comparator
    Placebo product

    Placebo gel

    Drug: Placebo gel

Interventions

06

What researchers measure

Primary outcomes

  1. Mean Percent Change From Baseline to Day 84 in Inflammatory (Papules and Pustules) Lesions

    Time frame: 84 days

  2. Mean Percent Change From Baseline to Day 84 in Non-inflammatory (Open and Closed Comedones) Lesions

    Time frame: 84 days

07

Results

Posted Jan 20, 2021

Participant flow

Participant flow — Overall Study
MilestoneTest ProductReference ProductPlacebo Product
Started365360178
Completed330307159
Not completed355319

Outcome measures

PrimaryMean Percent Change From Baseline to Day 84 in Inflammatory (Papules and Pustules) Lesions
Time frame:
84 days
Reported as:
Mean · percent change of lesion counts
Mean Percent Change From Baseline to Day 84 in Inflammatory (Papules and Pustules) Lesions
percent change of lesion countsTest ProductReference ProductPlacebo Product
Mean Percent Change From Baseline to Day 84 in Inflammatory (Papules and Pustules) Lesions61.07 ± 36.665.58 ± 28.4241.63 ± 28.05
Statistical analysis
  • Test Product vs Reference Product · Fieller's method · Equivalence ratio: 93.12 · 90% CI 88.6 to 102.00
PrimaryMean Percent Change From Baseline to Day 84 in Non-inflammatory (Open and Closed Comedones) Lesions
Time frame:
84 days
Reported as:
Mean · percent change of lesion counts
Mean Percent Change From Baseline to Day 84 in Non-inflammatory (Open and Closed Comedones) Lesions
percent change of lesion countsTest ProductReference ProductPlacebo Product
Mean Percent Change From Baseline to Day 84 in Non-inflammatory (Open and Closed Comedones) Lesions54.33 ± 32.0055.06 ± 32.6236.40 ± 38.61
Statistical analysis
  • Test Product vs Reference Product · Fieller's method · Equivalence ratio: 98.7 · 90% CI 92.3 to 109.4

Adverse events

Collected over 84 Days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Test Product0/365 (0%)0/365 (0%)0/365 (0%)
Reference Product0/360 (0%)2/360 (0.6%)0/360 (0%)
Placebo Product0/178 (0%)2/178 (1.1%)0/178 (0%)
Most frequent serious events
Most frequent serious events
EventTest ProductReference ProductPlacebo Product
GastroenteritisInfections and infestations0/3650/3601/178
Abortion SpontaneousPregnancy, puerperium and perinatal conditions0/3650/3601/178
ConvulsionNervous system disorders0/3651/3600/178
AppendicitisInfections and infestations0/3651/3600/178

Baseline characteristics

Age, Continuous
Age, Continuous(years)Test ProductReference ProductPlacebo ProductTotal
Mean19.9 ± 6.2520.4 ± 6.9619.5 ± 6.5520.0 ± 6.60
Sex: Female, Male
Sex: Female, Male(Participants)Test ProductReference ProductPlacebo ProductTotal
Female199213103515
Male16614775388
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Test ProductReference ProductPlacebo ProductTotal
Hispanic or Latino705927156
Not Hispanic or Latino295301151747
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Test ProductReference ProductPlacebo ProductTotal
American Indian or Alaska Native2417
Asian1719743
Native Hawaiian or Other Pacific Islander4217
Black or African American738734194
White259245132636
More than one race6309
Unknown or Not Reported4037
08

Study locations

No study locations are listed for this record.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2011, a primary completion of Aug 2012 and a completion of Aug 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2021, 8 years 5 months after primary completion. A results delay was requested in Aug 2015.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2015
First posted
Aug 17, 2015
Start
Dec 2011
Primary completionActual
Aug 2012
CompletionActual
Aug 2012
Results delay requested
Aug 17, 2015
Results first posted
Jan 20, 2021
Last update
Nov 2, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 2, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02525549
Lead sponsor
Padagis LLC
Responsible party
Sponsor
First posted
Aug 17, 2015
Start date
Dec 2011
Primary completion
Aug 2012
Completion
Aug 2012
Results posted
Jan 20, 2021
Last update
Nov 2, 2021

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Adapalene · Benzoyl Peroxide

Start the discussion